SG11202108905UA - Crystalline form of an avibactam derivative - Google Patents
Crystalline form of an avibactam derivativeInfo
- Publication number
- SG11202108905UA SG11202108905UA SG11202108905UA SG11202108905UA SG11202108905UA SG 11202108905U A SG11202108905U A SG 11202108905UA SG 11202108905U A SG11202108905U A SG 11202108905UA SG 11202108905U A SG11202108905U A SG 11202108905UA SG 11202108905U A SG11202108905U A SG 11202108905UA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline form
- avibactam derivative
- avibactam
- derivative
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817243P | 2019-03-12 | 2019-03-12 | |
| PCT/US2020/021795 WO2020185729A1 (en) | 2019-03-12 | 2020-03-10 | Crystalline form of an avibactam derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108905UA true SG11202108905UA (en) | 2021-09-29 |
Family
ID=70155371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108905UA SG11202108905UA (en) | 2019-03-12 | 2020-03-10 | Crystalline form of an avibactam derivative |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11008321B2 (en) |
| EP (1) | EP3938366A1 (en) |
| JP (1) | JP2022524118A (en) |
| KR (1) | KR20210137159A (en) |
| CN (1) | CN113614084A (en) |
| AU (1) | AU2020237440B2 (en) |
| BR (1) | BR112021017874A2 (en) |
| CA (1) | CA3133071A1 (en) |
| MX (1) | MX2021011026A (en) |
| SG (1) | SG11202108905UA (en) |
| WO (1) | WO2020185729A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210186983A1 (en) * | 2019-12-20 | 2021-06-24 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3658849A (en) | 1969-02-19 | 1972-04-25 | Reynolds Tobacco Co R | Treatment of 2-substituted aldehydes with lead dioxide |
| DE3045373A1 (en) | 1980-12-02 | 1982-07-01 | Henkel KGaA, 4000 Düsseldorf | Use of 3-hydroxy-2,2-di:methyl-propionate ester(s) as fragrances - including new propyl ester |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
| FR2812635B1 (en) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| UY30244A1 (en) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | A PROCESS TO PREPARE DERIVATIVES OF TETRAHYDROQUINOLINE |
| WO2009033054A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009052191A1 (en) | 2007-10-15 | 2009-04-23 | Xenoport, Inc. | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| UA101966C2 (en) | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
| GB0801401D0 (en) | 2008-01-25 | 2008-03-05 | Barry Callebaut Ag | Composition |
| WO2009100045A1 (en) | 2008-02-04 | 2009-08-13 | Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| CA2735929C (en) | 2008-09-19 | 2013-12-17 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| CN102638981B (en) | 2009-10-14 | 2015-07-22 | 默沙东公司 | Substituted piperidines that increase p53 activity and the uses thereof |
| PL2562155T3 (en) | 2010-04-20 | 2019-10-31 | Fujifilm Toyama Chemical Co Ltd | Hydroxamic acid derivative |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012086241A1 (en) | 2010-12-22 | 2012-06-28 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | Optically-active diazabicyclooctane derivative and method for manufacturing same |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| HUE027447T2 (en) | 2011-05-30 | 2016-09-28 | Sumitomo Chemical Co | Cyclohexanone compounds and herbicides comprising the same |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| AU2015316401A1 (en) | 2014-09-12 | 2017-04-06 | Fujifilm Toyama Chemical Co., Ltd. | Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof |
| KR20170047390A (en) | 2014-09-12 | 2017-05-04 | 토야마 케미칼 컴퍼니 리미티드 | Method for using novel hydroxamic acid derivative and antibacterial substance in combination |
| WO2016116788A1 (en) | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| JP2018515481A (en) | 2015-09-16 | 2018-06-14 | シュアンチュー ファーマ カンパニー，リミティド | β-lactamase inhibitors and uses thereof |
| US20170165371A1 (en) | 2017-02-22 | 2017-06-15 | Joel Steven Goldberg | Novel synthesis of potential ester prodrugs |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| JP6991345B2 (en) | 2017-10-02 | 2022-01-12 | アリクサ ファーマシューティカルズ、インコーポレイテッド | Aztreonam derivatives and their use |
-
2020
- 2020-03-10 AU AU2020237440A patent/AU2020237440B2/en active Active
- 2020-03-10 KR KR1020217032514A patent/KR20210137159A/en not_active Application Discontinuation
- 2020-03-10 CA CA3133071A patent/CA3133071A1/en not_active Abandoned
- 2020-03-10 WO PCT/US2020/021795 patent/WO2020185729A1/en active Application Filing
- 2020-03-10 EP EP20716651.3A patent/EP3938366A1/en not_active Withdrawn
- 2020-03-10 CN CN202080017829.6A patent/CN113614084A/en active Pending
- 2020-03-10 BR BR112021017874A patent/BR112021017874A2/en not_active Application Discontinuation
- 2020-03-10 MX MX2021011026A patent/MX2021011026A/en unknown
- 2020-03-10 SG SG11202108905UA patent/SG11202108905UA/en unknown
- 2020-03-10 US US16/813,930 patent/US11008321B2/en active Active
- 2020-03-10 JP JP2021553272A patent/JP2022524118A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210137159A (en) | 2021-11-17 |
| AU2020237440B2 (en) | 2022-10-20 |
| JP2022524118A (en) | 2022-04-27 |
| BR112021017874A2 (en) | 2021-12-07 |
| US11008321B2 (en) | 2021-05-18 |
| US20200291022A1 (en) | 2020-09-17 |
| AU2020237440A1 (en) | 2021-09-09 |
| CA3133071A1 (en) | 2020-09-17 |
| CN113614084A (en) | 2021-11-05 |
| MX2021011026A (en) | 2021-10-13 |
| WO2020185729A1 (en) | 2020-09-17 |
| EP3938366A1 (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| IL276644A (en) | Novel crystalline forms | |
| IL286218A (en) | Solid state forms of ripretinib | |
| EP4120820A4 (en) | Crystalline psilacetin derivatives | |
| EP3684358A4 (en) | New crystalline polymorph of ponesimod | |
| IL282552A (en) | Crystalline forms of mnk inhibitors | |
| EP3613733A4 (en) | Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride | |
| IL276592A (en) | Derivatives of sobetirome | |
| EP3250562A4 (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| EP3897660A4 (en) | Novel crystalline forms of an nrtti compound | |
| IL290964A (en) | 2-aminoquinazolinone derivative | |
| SI3749673T1 (en) | Crystalline form of bictegravir sodium | |
| EP3247399A4 (en) | Crystalline forms of efinaconazole | |
| IL276853A (en) | Crystalline forms of an sgc stimulator | |
| EP3793980A4 (en) | Crystalline form of s-apomorphine | |
| EP3456729A4 (en) | Crystalline polymorph of 15 -hydroxy-osaterone acetate | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
| SG11202100267TA (en) | Solid forms of an azolopyrimidine compound | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL285493A (en) | Crystalline forms of an rsk inhibitor | |
| EP3687987A4 (en) | Crystalline forms of lenalidomide |